Why the study?
Does rituximab 1,000 mg on days 1 and 15 improve overall response compared to rituximab 375 mg/m2 weekly for 4 weeks in adult patients with primary immune thrombocytopenia?
Population
107 adult patients with previously primary immune thrombocytopenia (ITP)
Comparison
Rituximab 1,000 mg on days 1 and 15 vs Rituximab 375 mg/m2 weekly for 4 weeks
Design
Cohort
Follow-up
12 months
Authors
Loading...
May support the alternative regimen as a convenient option in ITP; leaves open randomized confirmation of equivalence.
Does rituximab 1,000 mg on days 1 and 15 improve overall response compared to rituximab 375 mg/m2 weekly for 4 weeks in adult patients with primary immune thrombocytopenia?
The rituximab regimen of 1,000 mg on days 1 and 15 is an effective and safe alternative to the standard 4-week regimen for adults with immune thrombocytopenia.
Mahévas et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: